Compare Equinor ASA (EQNR) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Travere Therapeutics Inc. Common Stock — how do they compare? Equinor ASA trades at $44.92 (market cap $105.42B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Equinor ASA is far larger — about 21.6× Travere Therapeutics Inc. Common Stock's market cap, and Equinor ASA pays a 3.47% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EQNR | TVTX | |
|---|---|---|
Market Cap | $105.42B | $4.88B |
Volume | 4,977,357 | 1,668,577 |
Sector | Energy | Health |
52-Week High | $45.75 | $67.52 |
52-Week Low | $22.41 | $26.79 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $114.11B | $5.01B |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $45.29, up 3.07% today, with a bullish technical signal from moving averages and a consensus analyst price target of $87.50 implying significant upside. Recent earnings show a mix of beats and one miss, while fundamentals reveal strong cash flow from operations of $20.0B in 2025 and attractive valuation ratios, including a P/E of 12.2 and EV/EBITDA of 2.47. The company is expanding its LNG portfolio and executing share buybacks, supporting positive sentiment.
The outlook for EQNR is positive, driven by undervaluation relative to analyst targets and strategic growth in LNG and carbon capture. Key risks include volatility in energy prices and execution of expansion plans. Earnings growth and dividend stability remain central to investor appeal, with the stock positioned for potential appreciation if operational targets are met.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
